Skip to main content
Research CombinationMuscle GrowthRecoveryPreclinical EvidenceEducational · Not medical advice

CJC-1295 + Ipamorelin + BPC-157: Recovery & GH

A popular performance and recovery stack combining the GH secretagogue synergy of CJC-1295 and Ipamorelin with BPC-157's direct tissue healing and anti-inflammatory effects. The GH component supports protein synthesis, body composition, and systemic recovery, while BPC-157 targets localised tissue repair, tendon and ligament healing, and gut integrity. This three-peptide combination is widely used by athletes seeking both systemic anabolic support and targeted injury recovery simultaneously.

3
Compounds
Preclinical
Evidence Level
3
Research Refs
Muscle Growth
Primary Goal

Mechanism

Compound 1Recovery

BPC-157

The primary localised repair agent, targeting tendon, ligament, and muscle healing while also supporting gut integrity — the most common acute recovery bottleneck in high-load training contexts.

Compound 2Fat Loss

CJC-1295

Provides the GHRH backbone for sustained GH secretion, supporting systemic protein synthesis, body composition, and broader recovery alongside BPC-157's targeted tissue repair.

Compound 3Performance

Ipamorelin

Complements CJC-1295 with selective ghrelin-receptor stimulation to enhance GH pulse amplitude while avoiding the cortisol and prolactin elevation associated with less selective secretagogues.

Synergistic Effect

Triple-pathway activation

BPC-157 × CJC-1295 × Ipamorelin

Safety Notes

All three are unapproved research compounds. The CJC-1295 and Ipamorelin components are contraindicated in active or hormone-sensitive malignancies due to GH stimulation. BPC-157 has demonstrated pro-angiogenic properties in animal models, extending the malignancy caution to the full stack. No formal safety data exists for this triple combination; each compound's individual risk profile applies independently.

Research References

Per-component source only — no combination study exists

Emerging

Prolonged stimulation of GH and IGF-I secretion by CJC-1295

J Clin Endocrinol Metab 2006PMID 16822960
Emerging

Ipamorelin, the first selective growth hormone secretagogue

Eur J Endocrinol 1998PMID 9849822
Emerging

Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract

Curr Pharm Des 2011PMID 21548867
Browse all →

⚠ Educational Use OnlyPeptideBase provides educational research tools and provider discovery. It does not provide medical advice, diagnosis, treatment, prescribing guidance, or dosing instructions. Consult a qualified healthcare professional before making health decisions.

Free newsletter

The Peptide Research Digest

Weekly analysis on providers, sourcing and compounds — from the team behind PeptideBase.

No spam. Unsubscribe anytime. Privacy policy.